KTRA
NASDAQKintara Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News · 26 weeks10%
2025-12-072026-05-31
Mix190d
- Other1(100%)
Latest news
25 items- PRCraig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related CancersDistinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by blockbuster successes in hematology and oncology Coordinated and achieved more than 30 Oncology regulatory approvals and 15 new medical entity approvals, including four biologic or cell therapy approvals for various stages of multiple myeloma currently generating more than $16 billion in worldwide sales TAMPA, Fla., March 23, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced Dr. Craig L. Tendler will provide strat
- PRRakovina Therapeutics Highlights Strength of Scientific Advisory Board Driving Innovation in AI-Enabled Oncology Drug DevelopmentVANCOUVER, British Columbia, July 10, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. ("Rakovina" or the "Company") (TSXV:RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to highlight the strength and scientific leadership of its established Scientific Advisory Board (SAB). Rakovina's SAB is composed of internationally recognized experts in oncology, AI-driven drug development, and precision medicine. The board plays a vital role in shaping the company's research strategy, pipeline advancement, and translational development initiatives. Rakovina's Scientific Advisory
- INSIDERSEC Form 4 filed by Chief Scientific Officer Yamashita Dennis4 - Kintara Therapeutics, Inc. (0001498382) (Issuer)
- INSIDERNew insider Patel Vijay claimed ownership of 7,999,557 shares (SEC Form 3)3 - Kintara Therapeutics, Inc. (0001498382) (Issuer)
- INSIDERSEC Form 4 filed by Director Ng George K4 - Kintara Therapeutics, Inc. (0001498382) (Issuer)
- INSIDERNew insider Ng George K claimed no ownership of stock in the company (SEC Form 3)3 - Kintara Therapeutics, Inc. (0001498382) (Issuer)
- INSIDERSEC Form 4 filed by Director List Alan4 - Kintara Therapeutics, Inc. (0001498382) (Issuer)
- INSIDERNew insider List Alan claimed no ownership of stock in the company (SEC Form 3)3 - Kintara Therapeutics, Inc. (0001498382) (Issuer)
- INSIDERSEC Form 4 filed by Director Manuso James S J4 - Kintara Therapeutics, Inc. (0001498382) (Issuer)
- INSIDERNew insider Manuso James S J claimed no ownership of stock in the company (SEC Form 3)3 - Kintara Therapeutics, Inc. (0001498382) (Issuer)
- INSIDERNew insider Yamashita Dennis claimed no ownership of stock in the company (SEC Form 3)3 - Kintara Therapeutics, Inc. (0001498382) (Issuer)
- INSIDERChief Executive Officer Bianco James A. was granted 2,323,307 shares (SEC Form 4)4 - Kintara Therapeutics, Inc. (0001498382) (Issuer)
- INSIDERNew insider Bianco James A. claimed no ownership of stock in the company (SEC Form 3)3 - Kintara Therapeutics, Inc. (0001498382) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Dearborn Dan4 - Kintara Therapeutics, Inc. (0001498382) (Issuer)
- INSIDERNew insider Dearborn Dan claimed no ownership of stock in the company (SEC Form 3)3 - Kintara Therapeutics, Inc. (0001498382) (Issuer)
- SECKintara Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Leadership Update, Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Material Modification to Rights of Security Holders, Changes in Control of Registrant8-K - Kintara Therapeutics, Inc. (0001498382) (Filer)
- PRKintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024SAN DIEGO, Oct. 16, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. ("Kintara") (NASDAQ:KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced a correction to the press release previously issued by Kintara on October 16, 2024. Kintara announced today that its Board of Directors (the "Board") has approved a reverse stock split of Kintara's common stock at a ratio of 1-for-35. Kintara's common stock is expected to begin trading on a post-reverse stock split basis on the Nasdaq Capital Market on October 18, 2024, under the new name TuHURA Biosciences, Inc. and under the new symbol "HURA" following the anticipated closing of the merger
- PRKintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA BiosciencesSAN DIEGO, Oct. 16, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. ("Kintara") (NASDAQ:KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that its Board of Directors (the "Board") has approved a reverse stock split of Kintara's common stock at a ratio of 1-for-35. Kintara's common stock is expected to begin trading on a post-reverse stock split basis on the Nasdaq Capital Market on October 17, 2024, under the new name TuHURA Biosciences, Inc. and under the new symbol "HURA" following the anticipated closing of the merger (the "Merger") with TuHURA Biosciences, Inc. ("TuHURA"), with a new CUSIP number 898920 103.
- SECSEC Form EFFECT filed by Kintara Therapeutics Inc.EFFECT - Kintara Therapeutics, Inc. (0001498382) (Filer)
- SECKintara Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Kintara Therapeutics, Inc. (0001498382) (Filer)
- PRKintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024SAN DIEGO, Oct. 15, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. ("Kintara") (NASDAQ:KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced a correction to the press release previously issued by Kintara on October 14, 2024, regarding a record date for the issuance of the Contingent Value Rights ("CVRs") to stockholders of Kintara pursuant to the definitive merger agreement (the "Merger Agreement") with TuHURA Biosciences, Inc. ("TuHURA"). Kintara announced today that the CVRs will not be issued to stockholders of record of Kintara based on a record date of October 17, 2024, but rather will be issued stockholders of record of Kint
- SECKintara Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Kintara Therapeutics, Inc. (0001498382) (Filer)
- PRKintara Therapeutics Announces Record Date for CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024SAN DIEGO, Oct. 14, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. ("Kintara") (NASDAQ:KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced a record date of October 17, 2024 (the "Record Date") for the issuance of Contingent Value Rights ("CVRs") to stockholders of record of Kintara as of the Record Date. As previously disclosed, in April 2024 Kintara entered into a definitive merger agreement (the "Merger Agreement") with TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, and Kayak Mergeco, Inc., Kintara's wholly
- SECSEC Form POS AM filed by Kintara Therapeutics Inc.POS AM - Kintara Therapeutics, Inc. (0001498382) (Filer)
- SECKintara Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Kintara Therapeutics, Inc. (0001498382) (Filer)
KTRA FAQ
6 questionsWhat does Kintara Therapeutics Inc. do?
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic...Where does KTRA stock trade?
Kintara Therapeutics Inc. (KTRA) is listed on NASDAQ.What sector and industry is KTRA in?
Kintara Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about KTRA?
Kintara Therapeutics Inc. has had 3 recent analyst actions on file. The most recent action was from HC Wainwright & Co.: Buy with a $300.00 price target on 2022-01-20. Recent price targets range from $300.00 to $600.00.What companies are similar to KTRA?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare KTRA side-by-side with any of them on Quantisnow.How can I track KTRA on Quantisnow?
Quantisnow aggregates Kintara Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KTRA to receive live email and push alerts on every new disclosure.